Interim Analysis of Phase III Study Shows TAXOTERE Based Regimens With HERCEPTIN Significantly Improved Disease Free Survival in Women With Early-Stage HER2-Positive Breast Cancer
8th Dec 2005, 18:19 GMT
Results from the BCIRG 006 study also show that a novel non-anthracycline-based regimen (""TCH"") with TAXOTERE(R) (docetaxel), the platinum salt carboplatin and HERCEPTIN(R) (trastuzumab) reduces the risk of recurrence without increasing cardiotoxicity in patients with early stage HER2-positive breast cancer
Interim Analysis of Phase III Study Shows TAXOTERE Based Regimens With HERCEPTIN Significantly Improved Disease Free Survival in Women With Early-Stage HER2-Positive Breast Cancer related news:
- Combining herceptin with chemotherapy improves survival in breast cancer — KeralaNext: Health
- Herceptin Plus Chemotherapy Improves Disease-free Survival In Early Breast Cancer — ScienceDaily Headlines: Health & Medicine
- SABCS: Herceptin-Anthracycline Cardiotoxicity Called Real and Persistent — MedPage Today Hematology/Oncology
- Herceptin promising in early breast cancer — United Press International - Health Business
- SABCS: Taxotere-Cytoxan Combo Shows Survival Advantage in Breast Cancer Adjuvant Therapy — MedPage Today.com Latest Headlines
- Breast cancer drug halves return risk — the Mail online | Health
- Chemo regimen can limit Herceptin heart risk-study (Reuters) — Yahoo! News: Health News
- Chemo regimen can limit Herceptin heart risk-study — Reuters: Health
- Survival Benefit For Arimidex™ In Early Breast Cancer — Medical News Today RSS/XML Feed
- Positive ABRAXANE Data in Early-Stage Breast Cancer and Solid Tumors Reported at San Antonio Breast Cancer Symposium — Radiology News from StratCenter.com